Introduction {#Sec1}
============

Human embryonic stem cells (ESC) can provide a potential source of cells for research, regenerative medicine or tissue bioengineering \[[@CR1]\]. However, there are limitations that must be overcome, such as immune rejection and ethical and technical issues surrounding the use of human embryos as an ESC source for use in the clinic \[[@CR2]--[@CR4]\]. ESCs represent the prototypical stem cell: they have unlimited clonogenic and self-renewal capacity, and have the pluripotent potential required to all cellular lineages from a single cell. Thus, ESCs under specific stimuli can progress from a pluripotent state, competent to generate all cellular lineages, to a highly committed state characterized by a severe limitation of their differentiatiative potential \[[@CR5]\]. This developmental paradigm can be exploited in vitro to direct human ESCs into all the lineages present in the adult organism \[[@CR6]\]. Once this process starts, ESCs differentiative potential decreases concurrently with an acquisition of lineage specification \[[@CR7]\].

For many years, this process was considered permanent and irreversible. Two key experiments dispute this. The first, performed almost 6 decades ago in John Gurdon\'s lab, where whole new frogs were developed from reprogrammed "zygotes" obtained by injecting the nucleus from an adult somatic cell into an enucleated oocyte \[[@CR8]--[@CR10]\]. More recently, this observation was taken further when the first mammal (Dolly the sheep) was cloned from an adult somatic cell by nuclear transfer enucleated egg \[[@CR11]\]. This experiment essentially defined a new field of somatic cell reprogramming, and, in 2006, Takahashi and Yamanaka identified and defined a set of transcription factors which were able to reprogram somatic cells into a pluripotent state equivalent to that observed in the nuclear transfer studies. These cells were termed induced pluripotent stem cells (iPSCs) \[[@CR12]\]. Cells from several different organisms \[[@CR13]--[@CR15]\] and developmental origin have since been reprogrammed into iPSCs using combinations of transcription factors or/and microRNAs (miRNAs) \[[@CR16]--[@CR18]\].

Since the discovery of iPSCs, the notion that cells could be converted from one particular lineage to another, referred to as trans-differentiation, has gained in strength \[[@CR19]\]. Indeed, this was first demonstrated 2 decades ago by Weintraub, who showed that a single transcription factor, *MyoD*, could convert fibroblasts to myoblasts \[[@CR20]\]. In addition to this direct lineage conversion process, where one somatic cell is trans-differentiated into another cell type, recent data have established a further new concept termed "indirect" lineage-conversion, in which partial cellular reprogramming takes the cell to an intermediate "plastic" differentiation state from which progenitor-like cells finally differentiate \[[@CR21]--[@CR24]\]. This procedure has been investigated not only in cells cultured in vitro but also in disease target tissues in situ \[[@CR25], [@CR26]\].

All these conceptual breakthroughs are most certainly remarkable, but no less impressive have been the delivery techniques developed and used for such reprogramming \[[@CR18], [@CR27]\]. In Yamanaka\'s original work \[[@CR12]\], and in around 75 % of published reports, reprogramming has been achieved using either retroviral or lentiviral DNA vector integration. Genome modification in iPSCs represents a safety and therefore a regulatory obstacle for potential clinical application \[[@CR28]\] and has therefore been an area of significant interest characterized by a wide variety of different approaches \[[@CR27]\].

The initial generation of integrative viral vectors were followed by novel lentiviral vectors carrying poly-cistronic constructs flanked with *loxP* sites, which permitted Cre-dependent recombination and in order to minimize the footprint of genomic alterations \[[@CR29], [@CR30]\]. This solution still carried the risk of insertional mutagenesis, however, and to avoid this, retroviral and lentiviral transduction has been largely replaced by non-integrative methods. Thus, adenoviruses, which are non-integrating vectors, and remain in an epichromosomal form, have also been developed \[[@CR31]\]. Unfortunately, adenoviruses are cleared rapidly in dividing cells and gene expression is often not sufficient for efficient reprogramming. Alternatively, the piggyBac (PB) transposon system has allowed transposase-dependent integration and seamless excision of the reprogramming factors after pluripotency has been achieved in two steps by transient transposase expression. Although integrated piggyBac transposon vectors were designed to be removed without trace from the genome, transposition is not always precise, and sequence alterations have been reported in up to 5 % of the transpositions events \[[@CR32], [@CR33]\]. Additional non-integrating vector-based plasmids, episomal DNA, and minicircles have been developed to transiently express the reprogramming factors long enough to induce pluripotency \[[@CR34]--[@CR36]\]. However, the efficiency of these approaches remains low and exogenous DNA maintained in the cell becomes a potential risk for insertional mutagenesis and oncogenic transformation. Protein-based technology avoids these hurdles, although suffers from an extremely low efficiency, and requires either chemical treatment or extended periods of transduction \[[@CR37], [@CR38]\].

Perhaps the most promising technology that combines efficacy and safety features for future clinical application is based on RNA. Recent reports achieve reprogramming using Sendai virus-based vectors with a single strand RNA phase without DNA intermediate during transduction \[[@CR39]\], and sequential transfection of modified RNAs encoding the reprogramming transcription factors \[[@CR40]\]. In the rest of this article, I will discuss the novel advances in human reprogramming and some particularly interesting mouse lineage conversion examples, with a special emphasis upon the use of transgene-free RNA for cell-based therapies.

Transcription Factors, miRNAs, and Reprogramming {#Sec2}
================================================

Somatic cell reprogramming to iPSCs was first achieved by the expression of four different transcription factors: octamer-binding transcription factor 4 (*Oct4*), SRY-box- containing gene 2 (*Sox2*), Kruppel-like factor 4 (*Klf4*), and myelocytomatosis oncogene (*Myc*) \[[@CR12]\]. Soon after, human fibroblasts were successfully reprogrammed using a different combination of factors that included the Nanog homeobox protein (*NANOG*) and the RNA-binding protein Lin-28 homologue A (*LIN28A*) or suppressed the oncogenes *c*-*Myc* or *Klf4* \[[@CR41]\]. Given that pluripotency is a tight transcriptionally controlled state was not surprising that several groups demonstrated that miRNAs had roles in the regulation of stem cell differentiation \[[@CR17]\]. In fact, specific miRNA families could enhance or inhibit reprogramming demonstrating a role for these RNA molecules in pluripotency homeostasis \[[@CR42]\]. Members of specific pluripotency associated miRNAs families, like the *miR*-*302* family, have been shown to drive the initiation of a pluripotent state \[[@CR16], [@CR43], [@CR44]\]. Others, such as *miR*-*372* \[[@CR43]\], or a combination of *miR*-*200c*, *miR*-*302 s* and *miR*-*369s*were able to enhance reprogramming in human fibroblasts when used in combination with three of the four standard reprogramming factors (*Oct4*, *Sox2*, and *Klf4*) \[[@CR45]\]. On the other hand, negative regulation of set of tissue-specific miRNAs that includes *miR*-*21* \[[@CR46]\], *miR*-*29a* \[[@CR46]\], *miR*-*34* \[[@CR47]\], and *miR*-*199a*-*3p* \[[@CR48]\] demonstrated a suppressive role during reprogramming. In consequence, it is clear that overexpression or suppression of individual miRNAs have profound effects in iPSCs colony formation efficiency and stability \[[@CR49]\].

As can be appreciated above, in order to reprogram somatic cells into iPSCs, many reprogramming protocols have been described, using different combinations and variable sets of transcription factors and miRNAs \[[@CR27]\]. However, the choice of gene delivery system is the most critical aspect for the efficient and safe generation of iPSCs for future clinical applications. The delivery methods used so far for reprogramming can be classified in three categories depending on host genome alteration risk: DNA integrative (retrovirus, lentivirus, and transposons), non-integrative DNA-base (adenovirus, standard and episomal plasmids, and minicircles), and those that reprogram through a DNA-free approach (proteins, Sendai virus, and synthetic modified mRNA). In this latter group, we find the RNA-based methods that also accomplish the most promising efficiencies for future clinical application (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Efficiency versus safety to estimate reprogrammed cells future for clinical applications. Initially, reprogramming factors were delivered using DNA-integrative reprogramming methods. So far, these methods include (*1*) retrovirus, (*2*) lentivirus, including (*3*) Cre-*loxP*-mediated transgene excisable variants, and (*4*) transposons. These are followed by non-integrative DNA-based tools such as (*5*) adenovirus, (*6*) self-replicating episomal and (*7*) standard plasmids, and (*8*) minicircles. Finally, DNA-free approaches in nuclear reprogramming had been developed, such as (*9*) protein transduction and of particular success are the RNA-based tools like (*10*) the Sendai virus (SeV) and (11) synthetic modified mRNA (modRNA)

DNA-Integrative Reprogramming Tools {#Sec3}
===================================

DNA-integrative reprogramming methods reported so far include: (1) retrovirus, (2) lentivirus, including Cre-*loxP*-mediated transgene excisable variants, and (3) transposons.

Retroviral Reprogramming {#Sec4}
------------------------

Most researchers in the field still use integrative viral methods to reprogram differentiated cells into iPSCs, given that they are powerful gene delivery systems and are easily implemented in most research labs. In fact, the first iPSCs were reprogrammed using retroviral vectors to express each of the reprogramming factors \[[@CR12]\]. Retroviral vectors can be efficiently transduced into target cells and randomly integrated into the host genome of dividing cells. The reprogramming efficiency reported with this delivery system was 0.01--0.02 % in human cells \[[@CR50], [@CR51]\], which was increased to 0.25 % by the addition of *hTert* and SV-40 large T antigen to Yamanaka\'s factors \[[@CR52]\].

It should be emphasized that it is difficult to compare reprogramming efficiencies because of factors such as subjective criteria to calculate efficiency, use of different combinations of reprogramming factors, great variation in efficiency of different cellular source, and the use of small molecules to enhance reprogramming efficiencies.

Lentiviral Reprogramming {#Sec5}
------------------------

As retroviruses only infect dividing cells, there has been a shift to use lentiviral delivery systems so that both dividing and non-dividing cells could be infected, which means that it could be applied to a wide variety of cell types and improve reprogramming range and efficiency. Original work from the Thomson lab using *Sox2* and *Oct4* but replacing *Klf4* and *c*-*Myc* with *Nanog* and *Lin28A* generated iPSCs at an efficiency of 0.02 % \[[@CR41]\]. In addition, advanced inducible-lentiviral vector systems using doxycycline as an inducing agent have been used to exert specific control of the expression of the four transcription factors \[[@CR53], [@CR54]\]. Although acceptable gene delivery has been achieved using lentiviral vectors, concerns have often been raised regarding the incorporation of multiple copies of proviral sequences into the iPSC genome.

To tackle this concern lentiviral vectors were engineered with *loxP* sites in such a way that the reprogramming integrated factors could be excised by the transient expression of *Cre*-recombinase \[[@CR55]\]. In this *Cre*/*loxP* recombination system, a *loxP* site is inserted into the 3′ long-term repeat (*LTR*) of self-inactivating (*SIN*) lentiviral vectors, which contains the reprogramming factors. The *loxP* site is duplicated into the 5′*LTR* during proviral replication, resulting in host genomic integration with a transgene flanked by two *loxP* sites. Taking this approach, fibroblasts obtained from patients have been reprogrammed at efficiency over 1 % \[[@CR56]\]. However, after *Cre*-mediated recombination, a single *loxP* site flanked by small portions of the 5′ and 3′ *LTRs* is left behind as a footprint from every insertion/excision event. If more than one fragment remains in an iPSC\'s genomic DNA, the remaining *loxP* sites are a susceptible substrate for genome rearrangement \[[@CR57], [@CR58]\]. The presence of potentially unstable exogenous DNA is a definite safety concern if differentiated cells from these iPSCs are to be transplanted into patients.

Transposable Elements {#Sec6}
---------------------

In order to overcome problems associated with genomic alterations after viral vectors delivery of reprogramming factors, methods based on transposon/transposase system have been developed as an alternative \[[@CR32], [@CR33], [@CR59]\]. PiggyBac (PB) transposons, the most common transposon used in reprogramming, are mobile genetic elements that in the presence of its transposase can be integrated/excised at chromosomal TTAA sites \[[@CR60]\]. Recently, different laboratories have used this PB transposon/transposase system, which can be seamlessly removed following stable genomic integration, to successfully generate iPSCs from human fibroblasts at a rate between 0.02-0.05 % \[[@CR32], [@CR33]\]. Alternatively, sleeping beauty (SB) transposon system has also been used for cell reprogramming \[[@CR61], [@CR62]\]. Although, lack of SB transposon related sequence in human genome minimize potential cross-mobilization between endogenous and transposon sequences in comparison to PB \[[@CR63]\], the use of SB transposons implies that TA dinucleotide used as integration sites are changed to TAG(T/A)CTA after excision \[[@CR64]\]. This genome edition characteristic would diminish SB interest for future reprogramming use in clinic. Finally, it should be taken into account that transposon reversible integration/excision approach is complex and time consuming since identification of iPSCs with minimal-copy insertions, mapping of integration sites, excision of the reprogramming cassette, and validation of factor-free clones is required.

Non-Integrative DNA-Based Methodology {#Sec7}
=====================================

One of the major conceptual advances in the development of safer reprogramming technologies for clinical application was the observation that the integration of transcription factors into the genome is not required for the reprogramming of somatic cells. Non-integrative DNA-based tools used include (1) adenovirus, (2) standard and self-replicating episomal plasmids, and (3) minicircles.

Reprogramming with Adenoviral Vectors {#Sec8}
-------------------------------------

Adenoviral vectors are non-integrating double-stranded DNA vectors that remain in epichromosomal form in cells \[[@CR65]\]. At first glance, this appears to be an excellent alternative expression vehicle for generating iPSCs. However, the reprogramming efficiency of this method is only around 0.0002 % in human cells. Consequently, the reprogramming efficiency must be significantly improved before this delivery method can become clinically useful.

Standard and Self-Replicating Episomal Plasmids {#Sec9}
-----------------------------------------------

Ectopic expression of reprogramming factors from an episomal plasmid has also been explored as a possibility to generate footprint-free iPSCs. Unfortunately, transient transfection with a non-autonomous replicating plasmid does not result in expression for a sufficient period of time to reprogram somatic cells efficiently to iPSCs, and sequential transfections are required to achieve iPSCs \[[@CR66]\].

Unlike regular plasmids, episomal vectors derived from Epstein-Barr virus that contain *oriP*/*EBNA1* sequences can self-replicate once per cell cycle, albeit inefficiently. For this reason, iPSC lines normally lose the plasmid by their 15th passage in culture. Yu et al. successfully generated the first human iPSCs using an *oriP*/*EBNA1* episomal plasmid containing reprogramming factors, but reprogrammed colonies were observed at a very low frequency (0.0003--0.0006 %) \[[@CR67]\]. After clonal analysis, one third of subclones from two of the original iPSC lines had lost the episomal plasmid. Building on these results, Yamanaka and colleagues improved reprogramming efficiencies adding a short hairpin RNA (shRNA) against the tumor suppressor p53 to the cocktail to dedifferentiate adult peripheral blood mononuclear cells \[[@CR34], [@CR68]\]. However, p53 knockdown may raise concerns about genomic instability of iPS generated. Recently, this problem has been bypassed using, in the reprogramming mix, the anti-apoptotic factor Bcl-xl instead of the shRNA against p53 \[[@CR69]\]. Nevertheless, this technology will need further development to be applied therapeutically.

Non-Viral Minicircles {#Sec10}
---------------------

Minicircle vectors are circularized vectors in which the plasmid backbone has been released leaving only the eukaryotic promoter and cDNA(s) that are to be expressed. Using a minicircle vector expressing *Lin28A*, *Nanog*, *Sox2*,*Oct4*, and a GFP marker in human adipose stromal cells was able to reprogram 0.005 % of the cells. Surprisingly, this method was even less efficient at reprogramming neonatal fibroblasts, and no other reports have successfully reprogrammed other somatic cells \[[@CR70], [@CR71]\]. Therefore, more validation will be required before this method can be widely used.

DNA-Free Approaches {#Sec11}
===================

One common drawback of the delivery systems presented above, especially for those who want to take iPSCs from bench to bed, is the use of exogenous DNA sequences which are either integrated into the host genome or have the potential risk to do so. Growing concerns over the presence of transgene sequences in iPSCs have necessitated a number of astonishing recent technical developments. New tools include nonintegrative viral vectors or DNA-free approaches in nuclear reprogramming, such as (1) protein transduction, and in particular, RNA-based tools like (2) Sendai virus (SeV) and (3) synthetic modified mRNA (modRNA).

Reprogramming by Protein Transduction {#Sec12}
-------------------------------------

Direct protein transduction of reprogramming factors allows generation of footprint-free iPSCs. As such, this method could be another good choice for the creation of iPSCs suitable for studies in translational medicine. Unfortunately, it has been technically challenging to synthesize large amounts of bioactive proteins that can cross the plasma membrane, and very low efficiencies of 0.001 % in human cells have been reported \[[@CR37], [@CR38]\].

Viral RNA-Based Reprogramming Using Sendai Virus (SeV) {#Sec13}
------------------------------------------------------

SeV-based vectors are able to induce reprogramming factor expression without entering the nucleus of an infected cell and, crucially, this approach avoids any DNA phase, as the viral genome remains as RNA in the cytoplasm \[[@CR72]\]. SeV is an enveloped virus member of the family *Paramyxoviridae* with a nonsegmented negative-strand RNA genome \[[@CR73]\]. The SeV genome has 15,384 nucleotides and includes six cistrons \[[@CR74]\] (Fig. [2](#Fig2){ref-type="fig"}), which are organized as a single negative-strand RNA molecule. SeV genomic RNA forms a complex with nucleoprotein (NP), phosphoprotein (P), the small subunit of RNA polymerase, and the catalytic subunit of the polymerase called large protein (L) to form the ribonucleoprotein (RNP) macromolecule. Once in the cytoplasm, RNPs act as the template for transcription and replication. Matrix protein (M) engages in the assembly of viral particles with a large spherical shape and average diameter of 260 nm. Two envelope glycoproteins, hemagglutinin-neuraminidase (HN) and fusion (F) protein, which are integrated into lipid bilayers, mediate the attachment of virions to allow RNPs to penetrate into target cells. Viral infection depends on HN protein that recognizes the sialic acid, which is present as a glycoprotein or glycolipid on the cell surface \[[@CR75]\]. Sialic acid is widely expressed in mammalian cells, enabling SeV to target a broad cell type range \[[@CR76]--[@CR79]\]. The second envelope component, F protein, is synthesized as an inactive precursor protein F~0~ and split into F~1~ and F~2~ by proteolytic cleavage. Processed F protein penetrates into the cellular membrane to induce the bilipidic layer and viral envelope to merge \[[@CR80]\]. Once inside the infected cell, SeV vectors rely only on the virus-encoded RNA polymerase and ubiquitous cellular tubulin for their gene expression \[[@CR81]\]. In addition, SeV replication is independent of nuclear factors and does not involve a DNA phase. Therefore, it does not transform cells by integrating its genetic information into the cellular genome.Fig. 2Sendai virus (SeV) vector structure and recombinant infective particle generation. **a** Schematic representation of wild-type RNA SeV genomic organization. Infectively competent SeV-based vectors from first generation express genes of interest (GOI) from a 3′ wild-type SeV vector together with viral proteins NP, P, M, F, HN, and L (see text for details). Second-generation SeV vectors (infectively incompetent), include a T7 promoter and carry an F-defective SeV gene and termosensitive replicative proteins L\* and P\* genes. **b** Schematic representation of the two-step procedure for recovery of the F defective SeV vector. In the first step, the functional RNPs are recovered in LLC-MK2 or HEK293Tcells by expressing the viral proteins L, P, and NP together with T7 RNA polymerase. In the second step, RNPs are introduced via a cationic liposome to F-expressing LLC-MK2 cells (LLC-MK2/F7) to produce infectious F-defective virions

Since 1995, when the first recombinant SeV reconstitution from full-length genomic cDNA was completed, growing interest pushed forward the development of safer SeV vectors for clinical application \[[@CR82]\]. Several SeV vectors expressing genes of interest (*GOI*) have been generated based on the wild-type SeV strain (Fig. [2](#Fig2){ref-type="fig"}). The first generation SeV vectors used the region between the 3′ terminus and the *NP* gene of a full-length SeV genome to insert the *GOI*. At this location, SeV vectors maintain the replication capabilities and efficiently produced the GOI protein product when cultured in fertilized chicken eggs \[[@CR83]\]. However, for potential medical applications, defective SeV vectors that are unable to fuse cellular membranes were required; as a result of which, SeV vectors in which the F gene was deleted were developed.

These second generation vectors used F-defective SeV and a *GOI* \[[@CR72], [@CR84]\]. In principle, this SeV should be self-replication competent but unable to infect neighbor cells. Therefore, the recombinant SeV virus including a T7 promoter at the 3′ recovery in the laboratory must be achieved in two steps (Fig. [2](#Fig2){ref-type="fig"}). The first step involves RNPs generation from LLC-MK~2~ or HEK293T cells using an F-defective cDNA clone and plasmids expressing *NP*, *P*, *L* (*F5R* in alternative protocols) and the *T7 RNA*-*polymerase* genes. The second step is the isolation and transfection of functional RNPs into the F-expressing packaging cell line (LLC-MK~2~/F7), followed by collection of infectious particles from the supernatants. This second-generation SeV vector does not encode F protein itself, but instead incorporates it when expressed in *trans* from the packaging cells. Thus, using this approach in human fibroblasts, transgene-free iPSCs have been generated with efficiencies over 1.5 % \[[@CR39]\]. It should be noted that different cell types including fibroblasts, CD34^+^ cord blood cells \[[@CR85]\], and activated T-lymphocytes \[[@CR86], [@CR87]\] have been successfully reprogrammed using SeV F protein-deficient and termosensitive (ΔF/TS) vectors to date. Fully reprogrammed iPSCs with Yamanaka factors *Oct4*, *Sox2*, *Klf*, and *c*-*Myc* are able to passively eliminate viral RNA through successive cell passages \[[@CR39]\]. To achieve more effective RNA viral removal mutations in P and/or L replication, additional genes have been introduced to confer temperature sensitivity and then interfere with the RNP complex stability and viral replication \[[@CR88]\]. Importantly, it should be emphasized that improved recombinant SeV for nuclear reprogramming has been refined and are now commercially available.

To date, SeV vectors have proven to be an efficient method to deliver transgenes into a wide range of host cell species and tissues \[[@CR89]\]. SeV vectors have been already clinically applied in a gene therapy setting for different diseases such as cystic fibrosis \[[@CR77], [@CR90]\], critical limb ischemia \[[@CR91]\], and vaccines for AIDS \[[@CR92], [@CR93]\]. In the nuclear reprogramming context, the advantages brought by SeV technology are the following: (1) it is nonpathogenic to human, (2) it has a high efficiency of infection in dividing and quiescent cells, (3) it results in high levels of gene expression, (4) it is not integrative, and (5) it is controllably removable. Hence, recombinant SeV vectors are powerful tools for basic research, molecular therapy, and in regenerative medicine \[[@CR89], [@CR93]\].

Synthetic Modified mRNA (modRNA) for iPSC Derivation {#Sec14}
----------------------------------------------------

The ability to express reprogramming factors as mRNA offers another method to make DNA transgene-free iPSCs. Several technical hurdles have had to be overcome before making this a practical possibility, including efficient RNA synthesis, stability, and translation \[[@CR94]\] and lack of immunogenicity \[[@CR95], [@CR96]\]. Initially, to generate efficiently enough copies of target RNAs, chemical synthesis was unsuitable. The major technical obstacle was the limited yield obtained with this method. Yield decreases exponentially as transcripts grow since coupling efficiencies at each step are between 90--99 %. Thus it was not feasible to synthesize chemically very long RNA molecules. In contrast, bacteriophage polymerases, such as T7 RNA polymerase, are processive, and it is therefore possible to use in vitro transcription (IVT) to generate long RNA transcripts \[[@CR97]\]. These long RNA molecules have recently been used as reprogramming tools for the generation of iPSCs \[[@CR40], [@CR98]\].

In order to prepare the reprogramming DNA templates for IVT, the substrates include a *T7* promoter, 5′ *UTR*, 3′ *UTR*, and a *poly*-(*A*) tail to stabilize the RNA products \[[@CR97]\] (Fig. [3](#Fig3){ref-type="fig"}). Given the labile nature of RNA molecules, a key step in cellular mRNA processing is the addition of a 5′ cap structure, where 5′-5′ triphosphate is linked between the 5′ end of the RNA and a guanosine nucleotide. The cap is methylated enzymatically at the N-7 position of the guanosine to form mature mCAP \[[@CR99]\]. Processed 5′ cap adds stability to mRNA enhancing as well translation. Consequently, to stabilize modRNAs a cap have been incorporated to transcribed mRNA including a mixture of cap analog and GTP. The first cap analog used during IVT to generate stable modRNAs was mCAP \[m7G(5′)ppp(5′)G\] (Fig. [3](#Fig3){ref-type="fig"}). The inherent nature of the molecule implies that only 50 % of the time, mCAP was inserted in the correct orientation to enhance translation. The other 50 % of molecules were not substrates for efficient translation, reducing the specific activity of the RNA transcript to half. To avoid this problem, anti-reverse cap analog (ARCA) was introduced \[3′ O-Me-m7G(5′)ppp(5′)G\] \[[@CR100]\] (Fig. [3](#Fig3){ref-type="fig"}). Therefore, ARCA can only be inserted in the proper orientation, resulting in capped modRNAs that ones in the cell are translated twice as efficiently as those capped with mCAP. Although an improvement, and taking into account that reprogramming factor expression is typically robust only for about 24 h, whilst iPSCs generation requires several weeks to complete, there exists a need for successive transfections. This is an obvious handicap, since mRNA transfection induces the innate immune responses by activation of Toll-like receptors \[[@CR95]\] (TLR3, TLR7, and TLR8) and RNA sensors \[[@CR96], [@CR101]\] (RIG-I and PKR). Consequently, transfection of mRNAs into mammalian cells results in severe cytotoxicity. Surprisingly, incorporation of certain naturally occurring modified nucleosides into modRNA suppressed the activation of the innate immune response \[[@CR102]\]. As a result, 5-ribosyluracil (pseudo-UTP) \[[@CR98], [@CR103]\] and 5-methylcytidine-5′-triphosphate (5-Methyl-CTP) substitutions reduce in vitro toxicity. This reduced cytotoxicity has been critical for successful iPSC reprograming: several rounds of modRNA transfection can now be achieved.Fig. 3DNA template structure and key molecules used during modified mRNA (modRNA) synthesis. Linear in vitro transcription (IVT) templates incorporate a T7 promoter, 5′ and 3′ untranslated regions (UTRs) flanking an insertion site designed to accept a gene of interest (GOI) and a poly (A) tail. Modified capping molecule and nucleotides structure used for synthesis are also shown: anti reverse cap analog (ARCA) 3′-O-Me-m^7^G(5′)ppp(5′)G, pseudouridine-5\'-triphosphate (Pseudo-UTP) and 5-methylcytidine-5′-triphosphate (5-Methyl-CTP)

Pseudouridine (Fig. [3](#Fig3){ref-type="fig"}) was the first modified ribonucleoside discovered and the most abundant natural modified RNA base; as such, it has been considered the "fifth RNA nucleoside". It can be found in structural RNAs, such as transfer, ribosomal, and small nuclear RNAs. On the other hand, 5-Methyl-CTP (Fig. [3](#Fig3){ref-type="fig"}) can also be found in RNA molecules such as mRNA, miRNA, and tRNA as methylation of the position 5 of cytidine, given it is a common substrate for post-transcriptional modification \[[@CR104]\]. In the context of IVT, complete substitution of cytidine and uridine by pseudo-UTP and 5-Methyl-CTP increase modRNA stability against nuclease activities and translation, and reduce cytotoxicity by avoiding the activation of the immune response \[[@CR40]\]. These nucleoside substitutions allow robust and sustained protein expression. Combined with neutralizing type I interferon receptor supplements to completely suppress residual immune response, regular transfection of modRNAs encoding reprogramming factors (*Oct4*, *Sox2*, *Klf4*, *c*-*Myc*, *and Lin28A*) has led to successful iPSC reprogramming with efficiencies over 4 %. ModRNA technology allows iPSCs generation without residual traces of transgenes, making it an attractive option for cell-based therapies in translational research \[[@CR105]\]. Indeed, recent reports have demonstrated a potential therapeutical application for modRNA in vivo. Using a lung disease mouse model that lack surfactant protein B expression in the pulmonary epithelium, Kormann and colleagues have been able to rescue the wild-type phenotype by expressing surfactant protein B from a synthesized modRNA \[[@CR106]\]. Also mentioned here is that on top of this localized use, two groups have demonstrated that modRNA can be used to produce a systemic effect, over biologically active erythropoietin in vivo \[[@CR106], [@CR107]\].

Future Perspective for RNA-Technology in Cell-Fate Derivation {#Sec15}
=============================================================

The possibility of generating pluripotent cells from adult individual has obviously created enormous expectations, and has the potential to revolutionize the field of regenerative medicine. Once obtained, iPSCs are just the starting point for autologous cell therapies, and subsequent differentiation is essential. In other words, the final aim for cell-based therapies is to obtain enough committed progenitors or fully differentiated cells at will. In that sense, there are three possible sources from where to obtain these cells: (1) terminal differentiation from iPSCs (pluripotent state) to the required somatic cell types (ground state) \[[@CR108]--[@CR111]\]; (2) indirect lineage conversion from a somatic cell to a dedifferentiated activated state (progenitor-like state) that allows the commitment into several final cell lines in response to environmental signals and/or transcription factors \[[@CR22], [@CR24], [@CR112], [@CR113]\]; and (3) somatic cell direct linage conversion or *trans*-differentiation avoiding a progenitor-like state \[[@CR23], [@CR25], [@CR26], [@CR114]--[@CR116]\] (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Pathways to generate specific differentiated lineages from specific somatic cells. Fully differentiated target cells can be induced by three conceptually separate mechanisms: reprogramming (1) by ectopic expression of Yamanaka factors to induce a pluripotent state which can be later differentiated towards all lineages, (2) by indirect lineage-conversion where an activation phase is required to generate precursor-like cells, or (3) by direct lineage conversion with forced expression of lineage-specific transcription factors. Epigenetic modifications during indirect lineage-conversion are milder compared with the reprogramming process where all epigenetic marks are erased, in contrast to direct conversion which does not imply epigenetic modification

Forced expression of reprogramming factors induces a global dedifferentiation phenotype, which involves the removal of epigenetic marks and the reestablishment of the pluripotency network \[[@CR117]\]. Most differentiation protocols are inefficient, and derivation to several cell types is often complex. Cardiomyocyte differentiation of human iPSCs was first achieved by Zhang et al. who used the spontaneous embryoid-body based differentiation method \[[@CR109], [@CR110]\]. Some of the generated myocytes have been demonstrated to display molecular, structural, and functional properties of early human cardiomyocytes, showing different electrophysiological properties with ventricular-like, atrial-like, and nodal-like potential features \[[@CR108], [@CR110]\]. Human-derived cardiomyocyte are also able to display functional syncytium with stable pacemaker activity and synchronize action potential propagation \[[@CR118]\]. RNA-based tools are the most efficient and safest methods for iPSC generation \[[@CR40]\] (Fig. [1](#Fig1){ref-type="fig"}), and it is likely that these techniques could contribute greatly to the development of new differentiation procedures. Thus, it could be possible that SeV vectors or modRNA transient transfection encoding differentiation factors could be used to reset the epigenetic marks of a given cell type. Improvements in the differentiation efficiency would have a great impact on bringing iPSC technology closer to clinical application.

Direct lineage conversion, which does not involve an activation state, depends on whether defined factors are able to override epigenetic marks and drive *in trans* the establishment of the new target cell\'s genomic identity. Mouse fibroblasts, for instance, have been directly converted into cardiomyocytes by forced expression of cardiac-specific transcription factors *Gata4*, *Mef2c*, and *Tbx5* alone \[[@CR119]\], or together with Hand2 \[[@CR26]\]. Furthermore, in vivo *trans* expression of these genes in mouse heart fibroblasts after myocardial infarction can induce transdifferentiation into functional cardiomyocytes and improve heart function \[[@CR25], [@CR26]\]. These examples point to SeV tools as ideal for future use during direct lineage-conversion for several reasons. First, to overcome the existing epigenetic marks, strong and continuous expression of the *trans*-differentiating factors are crucial in order to induce direct lineage conversion. As discussed above, SeV constructs can drive ectopic overexpression of defined factors in any cell type that expresses tubulin. Second, specific epigenetic marks determine the accessible sites to which the *trans*-differentiating factors are able to transcribe from. Then, for a given combination of factors, the success in establishing a new determined network typical of a target cell will depend on matching genome accessibility of the original cell type. Hence, finding the best cellular source in combination with specific factors to directly convert one cell type into another could be challenging, although in the cardiac setting, heart-resident fibroblasts appear as the best substrate. As a typical recombinant viral vector, SeV is able to deliver transgenes more efficiently than a nonviral system. Its exceptionally broad host range gives SeV system a significant advantage over other methods. Since direct lineage-conversion occurs in the absence of a pluripotent state and generates post-mitotic populations, it could also theoretically reduce the risk of uncontrolled post-transplantation cell proliferation.

Indirect lineage conversion requires an activation state that leads to the generation of cellular intermediates, in which epigenetic marks get re-written \[[@CR21]\]. In this case, activated cells acquire a precursor-like phenotype with multipotent differentiation capacity. This is important, as generation of progenitor cells with such capabilities will expand applications in regenerative medicine, specifically in cases where progenitor transplantation might be an advantage over fully differentiated cells. Recent reports have demonstrated that short temporal expression of pluripotency factors was enough to induce a partially de-differentiated state suitable for conversion into specific cell types by extracellular developmental signals \[[@CR113]\]. More striking was the fact that cells in a more pluripotent stage diminished their lineage conversion efficiency, like it has been shown for mouse cardiomyocyte differentiation \[[@CR119]\]. These data indicate that the process itself must be fine-tuned in order to achieve partial reprogramming and start a differentiation route on time to obtain the target cell of interest. Synthetic modRNA technology presents a number of characteristics that make it a potential powerful platform for this type of indirect linage conversion. These features include the fact that modRNA enables robust and dose-titrable translation of nearly any protein. Moreover, since modRNA combination of multiple transcripts can be transfected into cells at once, co-translation of several factors at desired stoichiometry is simply controlled by changing the dose of the relevant modRNAs \[[@CR120]\]. To our knowledge, no other reprogramming technology permits such control over reprogramming factor expression. Remarkably, the labile nature of modRNAs inside the cells, (its half-life of around 24 h was originally considered a serious handicap) has become a powerful characteristic, differentiating it from alternative reprogramming vectors. As a consequence, modRNA stands out as an ideal tool to temporally and quantitatively control the expression of any given combination of factors in order to redefine cellular fate.

It is also noteworthy that RNA-based reprogramming methodology could easily take advantage of synthetic biology for further technical development. As emphasized throughout this review, using DNA-free delivery techniques abolishes the risk of random genomic integration and opens up the opportunity to develop safe artificial tools for reprogramming and/or lineage conversion. A recent example has demonstrated that reprogramming could be enhanced using engineered variants of *Oct4* fused to N-terminal *MyoD* transactivation domain \[[@CR121]\]. It is known that ectopic expression of *MyoD* is able to direct the fate of iPSCs towards a myogenic fate \[[@CR122]\], and is also able to induce *trans*-differentiation. Hence, this synthetic transcription factor maintains the powerful transactivation activity of *MyoD*, without losing the target specificity of *Oct4*. By modRNA transfection of this engineered factor chromatin accessibility and recruitment of chromatin remodeling proteins to the *Oct4* site can be increased, resulting in a radical acceleration of iPSCs derivation \[[@CR105]\].

Taken together, it seems possible that RNA-based technologies for reprogramming and encoding lineage specification factors could emerge as important tools for generating diverse cell types, either by terminal differentiation from iPSCs, or by direct or indirect lineage conversion, for experimental and future therapeutic applications.
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